Use of RIP in treating staphylococcus aureus infections
US7824691B2 · kind B2 · utility
1Cited by
8References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 3, 2006 |
| Grant date | Nov 2, 2010 |
| Priority date | — |
| Expiry date | Sep 11, 2028 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition is advantageously used in a method of treatment of bacterial sepsis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.